Navigation Links
Regado Biosciences Permanently Halts REGULATE-PCI Clinical Trial
Date:8/25/2014

cogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs. More information can be found at www.regadobio.com. For more information on REGULATE-PCI, please visit: http://www.clinicaltrials.gov/ct2/show/NCT01848106

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the progress of the REGULATE-PCI trial, the expected timing and outcome of our analysis of the unblended REGULATE-PCI database, the prospects for the continued development and any regulatory approval of Revolixys™ Kit and the successful commercialization of Revolixys™ Kit, if approved. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from those projected in forward-looking statements include the outcome of our database analysis, our determination of the safety and/or efficacy of Revolixys™ Kit as well as the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2014, and in the Company's other periodic filings with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights
2. Attention Regado Biosciences, Inc. Investors: Regado Misled Investors According to a Recently Filed Class Action
3. Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board
4. Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
5. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
6. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
7. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
8. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
9. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
10. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
11. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present a corporate overview at the 21 st ... The presentation will take place on Friday, September ... Hotel in New York, NY . A ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... (NYSE: HRC ) invites you to listen to ... Conference in New York City on February 15, 2012, at ... to the live discussion via the internet link at  http://ir.hill-rom.com/events.cfm ... recorded replay of the discussion will be available one hour ...
... growing stronger and stronger for one of the most ... on February 21-22, 2012 at the Renaissance Zurich Hotel ... 150 top pharmaceutical executives already attending, people are already ... among the industry,s influential decision makers," says conference organizer ...
Cached Medicine Technology:World's Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event 2
(Date:9/21/2014)... CareSpan USA, Inc. announced today at the ... services agreement with Avera eCARE, a leading healthcare system ... Clinic in multiple states where Avera eCARE is licensed. ... joint services in remote and rural parts of North ... licensed. The two companies’ strategy is to focus on ...
(Date:9/21/2014)... Dallas, Texas (PRWEB) September 22, 2014 ... was originally launched in 1997, and is used ... children and adults. Its active ingredient, budesonide, is ... the corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the ... older than six years of age, Pulmicort Respules ...
(Date:9/21/2014)... an allergy to peanuts than raw peanuts, suggests an ... that specific chemical changes caused by the high temperatures ... body,s immune system, ,priming, the body to set off ... any peanuts. , The results might explain the difference ... the Western world compared to populations in East Asia, ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... enabled more generic drugs to inundate the market, thereby ... Pharmaceutical Manufacturing industry. According to data from Industry ... has cost the industry $1.8 and $2.5 billion in ... brand-name drugs losing patent exclusivity, which has hampered revenue ...
(Date:9/21/2014)... "I want to help people who ... haven’t the money for chiropractors," said an inventor from ... a product for myself." , The Stretch is a ... thigh muscles and align the spine properly. It improves ... of pinched nerves. Compact and easy to use, it's ...
Breaking Medicine News(10 mins):Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Dry roasting could help trigger peanut allergy 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3
... Oral Suspension Also Approved--, WILMINGTON, Del., Feb. 28 ... and Drug Administration (FDA) has,approved the use of NEXIUM(R) ... for the short-term treatment of gastroesophageal reflux,disease (GERD) for ... unmet,need for pediatric patients., NEXIUM received approval in ...
... Hospital has entered,into an agreement with VISICU, Inc., ... and remote monitoring tools, eICU,technology enables off-site critical ... around the clock. The voice, video and data,technology ... rates and shorten hospital length of stay., ...
... Education, Body Mass Index training events for, physicians and ... ... adults, INDIANAPOLIS, Feb. 28 With obesity at the forefront ... the Indiana Department of Health today announced that they will be,hosting ...
... (NEWARK, N.J., Feb. 28, 2008) New Jersey State ... Administration Research Education) Award for Excellence in Research to ... Flynn, assistant professor at the College of Nursing at ... honored with three other C.A.R.E. award recipients during the ...
... technologies and ... medical advancements, AUSTIN, Texas, Feb. ... officially opened the expansion of its,heart hospital today with the introduction ... as the number one overall,cardiac program in the State of Texas ...
... CHICAGO, Feb. 28 The Female Health Company,(Amex: ... John Snow, Inc., which,implements the USAID | DELIVER PROJECT, ... the United States Agency for International,Development (USAID) programs., ... international donors,of contraceptives and condoms. The Agency developed an ...
Cached Medicine News:Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 2Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 3Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 4Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 5Health News:The Christ Hospital and VISICU Sign Agreement to Implement eICU(R) Program 2Health News:Anthem Blue Cross and Blue Shield Teams with the State of Indiana to Combat Obesity 2Health News:Anthem Blue Cross and Blue Shield Teams with the State of Indiana to Combat Obesity 3Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 2Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 3Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 4Health News:The Female Health Company Receives USAID DELIVER PROJECT Order for 6.1 Million Units 2
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile....
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic Economical Single use. Non-Sterile....
Medicine Products: